Autonomix Medical Inc Financials
This page shows Autonomix Medical Inc (AMIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Autonomix Medical Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Autonomix Medical Inc generates $0.73 in operating cash flow (-$8.3M OCF vs -$11.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Autonomix Medical Inc earns $-65.8 in operating income for every $1 of interest expense (-$11.6M vs $176K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Autonomix Medical Inc generated $0 in revenue in fiscal year 2025.
Autonomix Medical Inc reported -$11.4M in net income in fiscal year 2025. This represents an increase of 26.0% from the prior year.
Cash & Balance Sheet
Autonomix Medical Inc held $9.1M in cash against $0 in long-term debt as of fiscal year 2025.
Autonomix Medical Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 164.9% from the prior year.
Margins & Returns
Autonomix Medical Inc's ROE was -140.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 61.3 percentage points from the prior year.
Capital Allocation
Autonomix Medical Inc invested $4.7M in research and development in fiscal year 2025. This represents an increase of 112.4% from the prior year.
AMIX Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2K-99.9% | $1.7M-27.2% | $2.4M+48.6% | $1.6M | N/A | $1.0M-11.1% | $1.2M+23.1% | $954K |
| SG&A Expenses | $2K-99.9% | $1.6M-68.7% | $5.2M+182.7% | $1.8M | N/A | $1.7M+2.5% | $1.7M-7.6% | $1.8M |
| Operating Income | $3K+100.1% | -$3.3M+55.6% | -$7.5M-120.2% | -$3.4M | N/A | -$2.7M+3.1% | -$2.8M-3.0% | -$2.8M |
| Interest Expense | $0 | $0 | $0 | $0 | N/A | $100K0.0% | $100K+143.9% | $41K |
| Income Tax | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | $3K+100.1% | -$3.3M+56.2% | -$7.5M-123.3% | -$3.3M+70.8% | -$11.4M-320.7% | -$2.7M+3.4% | -$2.8M-4.0% | -$2.7M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AMIX Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10K-99.9% | $10.2M+28.7% | $7.9M-11.8% | $9.0M-8.3% | $9.8M-18.0% | $12.0M+122.5% | $5.4M-24.3% | $7.1M |
| Current Assets | $10K-99.9% | $10.2M+29.1% | $7.9M-12.1% | $9.0M-6.6% | $9.6M-19.5% | $11.9M+122.9% | $5.4M-24.3% | $7.1M |
| Cash & Equivalents | $10K-99.9% | $9.9M+32.9% | $7.5M-12.9% | $8.6M-6.0% | $9.1M-22.7% | $11.8M+129.4% | $5.2M-23.6% | $6.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2K-99.9% | $1.6M+11.0% | $1.5M-24.3% | $2.0M+15.1% | $1.7M-24.0% | $2.2M-4.2% | $2.3M+29.7% | $1.8M |
| Current Liabilities | $2K-99.9% | $1.6M+11.0% | $1.5M-24.3% | $2.0M+15.1% | $1.7M-24.0% | $2.2M+78.6% | $1.3M+64.7% | $763K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9K-99.9% | $8.6M+32.8% | $6.4M-8.3% | $7.0M-13.2% | $8.1M-16.6% | $9.7M+220.6% | $3.0M-42.7% | $5.3M |
| Retained Earnings | $64K+100.1% | -$64.4M-5.3% | -$61.2M-13.9% | -$53.7M-6.6% | -$50.4M-6.8% | -$47.2M-6.1% | -$44.5M-6.7% | -$41.7M |
AMIX Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $9K+100.3% | -$3.0M+22.2% | -$3.8M-46.6% | -$2.6M+68.5% | -$8.3M-258.9% | -$2.3M-44.2% | -$1.6M+13.8% | -$1.9M |
| Capital Expenditures | $7-99.9% | $7K | $0 | $0-100.0% | $14K+180.0% | $5K | $0-100.0% | $5K |
| Free Cash Flow | $9K+100.3% | -$3.0M+22.0% | -$3.8M-46.6% | -$2.6M+68.5% | -$8.3M-258.7% | -$2.3M-44.5% | -$1.6M+14.1% | -$1.9M |
| Investing Cash Flow | $7+100.1% | -$7K | $0 | $0+100.0% | -$14K-180.0% | -$5K | $0+100.0% | -$5K |
| Financing Cash Flow | $10K-99.8% | $5.4M+100.9% | $2.7M+31.5% | $2.1M-76.6% | $8.8M-1.9% | $9.0M | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AMIX Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 38.1%+76.2pp | -38.1%+77.5pp | -115.6%-68.1pp | -47.4%+93.4pp | -140.9%-112.9pp | -27.9%+64.8pp | -92.7%-41.7pp | -51.0% |
| Return on Assets | 31.9%+63.9pp | -31.9%+62.0pp | -93.9%-56.8pp | -37.1%+79.3pp | -116.4%-93.7pp | -22.7%+29.6pp | -52.3%-14.2pp | -38.0% |
| Current Ratio | 6.180.0 | 6.18+0.9 | 5.31+0.7 | 4.57-1.1 | 5.63+0.3 | 5.31+1.1 | 4.26-5.0 | 9.27 |
| Debt-to-Equity | 0.190.0 | 0.19-0.0 | 0.23-0.0 | 0.28+0.1 | 0.21-0.0 | 0.23-0.5 | 0.77+0.4 | 0.34 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Autonomix Medical Inc's annual revenue?
Autonomix Medical Inc (AMIX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Autonomix Medical Inc profitable?
No, Autonomix Medical Inc (AMIX) reported a net income of -$11.4M in fiscal year 2025.
What is Autonomix Medical Inc's return on equity (ROE)?
Autonomix Medical Inc (AMIX) has a return on equity of -140.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Autonomix Medical Inc's operating cash flow?
Autonomix Medical Inc (AMIX) generated -$8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Autonomix Medical Inc's total assets?
Autonomix Medical Inc (AMIX) had $9.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Autonomix Medical Inc spend on research and development?
Autonomix Medical Inc (AMIX) invested $4.7M in research and development during fiscal year 2025.
What is Autonomix Medical Inc's current ratio?
Autonomix Medical Inc (AMIX) had a current ratio of 5.63 as of fiscal year 2025, which is generally considered healthy.
What is Autonomix Medical Inc's debt-to-equity ratio?
Autonomix Medical Inc (AMIX) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Autonomix Medical Inc's return on assets (ROA)?
Autonomix Medical Inc (AMIX) had a return on assets of -116.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Autonomix Medical Inc's cash runway?
Based on fiscal year 2025 data, Autonomix Medical Inc (AMIX) had $9.1M in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Autonomix Medical Inc's Piotroski F-Score?
Autonomix Medical Inc (AMIX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Autonomix Medical Inc's earnings high quality?
Autonomix Medical Inc (AMIX) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Autonomix Medical Inc cover its interest payments?
Autonomix Medical Inc (AMIX) has an interest coverage ratio of -65.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.